Lineage Cell Therapeutics, Inc. Common Stock (LCTX)

Lineage Cell Therapeutics Q2 2025: Revenue beats estimates at $2.77M (+84.6%), but net loss widens to -$0.13. Stock dips 4.95% amid clinical progress and cash runway into 2027.

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.